SCFD1 is a Sec1 family protein that plays a critical role in intracellular vesicular transport, particularly in SNARE-pin assembly and ER-Golgi trafficking 1. It functions as a Sec1/Munc18-like regulatory protein that interacts with syntaxin 5 and the COG membrane tethering complex to mediate both anterograde ER-to-Golgi and retrograde Golgi-to-ER transport 1. SCFD1 is involved in post-Golgi vesicle-mediated transport and regulation of autophagosome assembly through its protein-binding interactions. Clinically, SCFD1 has emerged as a candidate therapeutic target for multiple neurodegenerative conditions. Genome-wide association studies identified SCFD1 as a risk locus for amyotrophic lateral sclerosis (ALS) 2, with proteome-wide association studies confirming its causal relationship with ALS risk 34. Additionally, integrative multi-omics analysis designated SCFD1 as a high-confidence therapeutic target for glioblastoma 5. In cancer biology, SCFD1 was upregulated in PD-1+ colon cancer cells treated with nivolumab, suggesting involvement in anti-PD-1 immunotherapy responses 6. While SCFD1 showed associations with skeletal muscle aging in neural network analyses 7, subsequent targeted validation failed to confirm its differential expression in aged muscle. These findings indicate SCFD1's multifaceted roles in neurodegeneration and cancer biology, warranting further functional validation.